Clinical Trial Search

Primary: Percentage of Patients Who Achieved Clinical Symptom Improvement by Randomization Stratum and Treatment. — 13.5; 28.2; 100; 20.0 Percentage of Participants

Primary: Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 15mg/dL (<75mg/dL) or Within +/- 20% (>=75mg/dL) of Laboratory Glucose Method — 100 percentage of BG…

Primary: Patient Overall Preference — 4.75; 2.45 units on a scale — p=<0.0001

Primary: Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84 — 0.094; 0.174 Liters — p=<0.001

Primary: Response: Change in Insomnia Severity Rating Scale at 3 Months. — 0.72; -4.01 units on a scale

Primary: Change in HbA1c From Baseline to Week 26 — -0.17; -0.79; -0.94; -0.82 Percent — p=<0.001

Primary: Attainment of Informed Consent as Measured by Consent Instrument (Consent-20) — 37.36; 33.2 Units on a scale — p=<0.0001

Primary: Change From Baseline Trough in 24-hour Weighted-mean FEV1 on Treatment Day 84 — 0.108; 0.130 Liters — p=0.282

Primary: Pain Intensity on a Visual Analog Scale (VAS) The Scale Had Values From 0-100, Where 0 Represents "no Pain" and 100 Was the "Worst Pain Imaginable". — 51.0; 51.6 peak…

Primary: Number of Patients With Complete Response — 14; 3 participants

Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms

Primary: Binge Frequency — 10.4; 11.3 Binge Episodes/Week — p=<.05

Primary: Overall Survival — 248; 253 Days — p=0.4687

Primary: The Difference of Time Spent in the 'on' State Without Troublesome Dyskinesia Based on Patient Motor Diaries as Compared to the Baseline. — 4.6; 0 Hours per day

Primary: Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF) — 38.05; 41.06 Percentage SMHR…